MET-88: SR Ca2+-uptake stimulator for treating chronic heart failure

Cardiovascular Drug Reviews

Volumn 17, Issue 1, 1999, Pages 75-86

  Kirimoto, Tsukasa ^a   Asaka, Naomasa ^a   Hayashi, Yukio ^a   Maeda, Toshimatsu ^b   Irimura, Kenji ^c   Matsuura, Naosuke ^a,c  

^a Pharmacological Research Laboratory   (Japan)

^b Pharmacokin Research Laboratories   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Glycolysis; MET 88; Myocardial energy metabolism; Myocardial function; Remodeling; SR Ca2+ uptake

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); MILDRONATE;

CALCIUM TRANSPORT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM;

EID: 0032796642     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00005.x     Document Type: Review

References (24)

1. Aoyagi T, Sugiura S, Eto Y, Yonekura K, et al. Inhibition of carnitine synthesis protects against left ventricular dysfunction in rats with myocardial ischemia. J Cardiovasc Pharmacol 1997;30:468-474.
2. Asaka N, Muranaka Y, Kirimoto T, et al. Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol 1998;12: 158-163.
3. Asaka N, Muranaka Y, Kirimoto T, et al. Cardioprotective profile of MET-88 in isolated perfused rat hearts. Eur Heart J 1994;93(Suppl):93.
4. Dahr PK, Grupp IL, Schwartz A, et al. Reduction of carnitine content by inhibition of its biosynthesis results in protection of isolated guinea pig hearts against hypoxic damage. J Cardiovasc Pharmacol Ther 1996; 1:235-242.
5. Garcia R, Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 1990;24:430-432.
6. Hasenfuss G, Meyer M, Schillinger W, et al. Calcium handling proteins in the failing human heart. Basic Res Cardiol 1997;92(Suppl I):87-93.
7. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-442.
8. Hashimoto K, Yabuuchi Y, Yamashita S, et al. Positive inotropic effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure. Arzneim Forsh Drug Res 1984;34:390-393.
9. Hayashi Y, Kirimoto T, Asaka N, et al. Beneficial effects of MET-88, a new cardioprotective agent, on ventricular remodeling in rats with chronic heart failure secondary to myocardial infarction. Jpn J Pharmacol 1995;67(Suppl I):P1-156.
10. Higgins CB, Pavelec R, Vatner SF. Modified technique for production of experimental right-sided congestive failure. Cardiovasc Res 1973;7:870-874.
11. Jeremy RW, Koretsune Y, Marban E, et al. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res 1992;70:1180-1190.
12. Johns TNP, Olson BJ. Experimental myocardial infarction: I. A method of coronary occlusion in small animals. Ann Surg 1954;5:140.
13. Kirimoto T, Asaka N, Hayashi Y, et al. The beneficial effects of MET-88 on cardiac hypertrophy by monocrotaline in rats. Jpn J Pharmacol 1997;73(Suppl I):132.
14. Kirimoto T, Hayashi Y, Miyake H, et al. MET-88, a new cardioprotective agent, improves experimentally induced heart failure in dogs. Jpn J Pharmacol 1995;67(Suppl I):S33-6.
15. Kirimoto T, Hayashi Y, Miyake H, et al. The beneficial effects of MET-88 on changes in myocardial pH and infarct size during coronary artery occlusion and reperfusion in dogs. Jpn J Pharmacol 1996;71(Suppl I):P-349.
16. Kirimoto T, Nobori N, Asaka N, et al. Beneficial effect of MET-88, γ-butyrobetaine hydroxylase inhibitor, or energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther 1996;331:163-178.
17. Lamers JMJ, Jonge-Stinis JT, Verdouw PD, et al. On the possible role of long chain acylcarnitine accumulation in producing functional and calcium permeability changes in membranes during myocardial ischemia. Cardiovasc Res 1987;21:313-322.
18. Linck B, Eschenhage T, Scholz H, et al. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996;31: 625-632.
19. Lopaschuk GD, Spafford M. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res 1989;65:378-387.
20. Lopaschuk GD, Wall SR, Olley PM, et al. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988;63:1036-1043.
21. Nakano M, Kirimoto T, Asaka N, et al. The beneficial effects of MET-88 on cardiac hypertrophy with volume overload in rats. Jpn J Pharmacol 1996;71(Suppl I):135.
22. Selye H, Bajusz E, Grasso S, et al. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 1960;11:398.
23. Simkhovich B, Shutenko Z, Meirena D, et al. 3-(2,2,2-Trimethylhydrazinium) propionate (THP): a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1987;37:195-202.
24. 2+ transport. Circ Res 1995;77:88-97.